Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 323-331

  Shinkai, Hisashi ^a  

^a JT Inc   (Japan)

Author keywords

Anacetrapib; Cardiovascular disease; CETP inhibitor; CETP modulator; Cholesteryl ester transfer protein (CETP); Dalcetrapib; High density lipoprotein

Indexed keywords

ANACETRAPIB; ANTILIPEMIC AGENT; ATORVASTATIN; DALCETRAPIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TORCETRAPIB; BIOLOGICAL MARKER; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVATIVE; THIOL DERIVATIVE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; NONHUMAN; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASCULAR DISEASE; ANIMAL; BLOOD; DRUG ANTAGONISM; DYSLIPIDEMIA; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; OXAZOLIDINONES; QUINOLINES; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84865624409     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S25238     Document Type: Review

References (38)

1. Bays H, Stein EA. Pharmacotherapy for dyslipidemia-current therapies and future agents. Expert Opin Pharmacother. 2003;4:1901-1938.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-714.
3. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med. 2010;153: 800-808.
4. Arsenault BJ, Barter P, DeMicco DA, et al. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2011;57:63-69.
5. Johnsen SH, Mathiesen EB, Fosse E, et al. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromsø study. Circulation. 2005;112:498-504.
6. Wei L, Murphy MJ, MacDonald TM. Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. Heart. 2006;92:746-751.
7. Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
8. Shepherd J, Betteridge J, Van Gaal L, et al. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin. 2005;21:665-682.
9. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res.1993;34: 1255-1274.
10. Marcel YL, McPherson M, Hogue H, et al. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J Clin Invest. 1990;85:10-17.
11. Ha YC, Gorjatschko L, Barter PJ. Changes in the density distribution of pig high density lipoproteins during incubation in vitro. Influence of esterified cholesterol transfer activity. Atherosclerosis 1983;48: 253-263.
12. Paromov VM, Morton RE. Lipid transfer inhibitor protein defines the participation of high-density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP). J Biol Chem. 2003;278:40859-40866.
13. Barter PJ, Brewer HB Jr, Chapman J, et al. Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vas Biol. 2003;23:160-167.
14. De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105(21):2159-2165.
15. Kuivenhoven JA, De Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol. 2005;95:1085-1088.
16. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet. 2007;370:1907-1914.
17. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2008;157(2):352-360.
18. Nicholls SJ, Brewer HB, Kastelein JJP, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statin on HDL and LDL cholesterol. A randomized controlled trial. JAMA. 2011;306(19):2099-2109.
19. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomized clinical trial. Lancet. 2011;378:1547-1559.
20. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. New Engl J Med. 2010;363(25):2406-2415.
21. Davidson MH. Update on CETP inhibition. J Clin Lipidology. 2010; 4(5):394-398.
22. Miyares MA. Anacetrapib and Dalcetrapib: Two novel cholesteryl ester transfer protein inhibitors. Ann Pharmacother. 2011;45(1):84-94.
23. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406(6792):203-207.
24. Qui X, Mistry A, Ammirati MJ, et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol. 2007;14(2):106-113.
25. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443-3454.
26. Lüscher T. Dalcetrapib passed test in dal-VESSEL: Raises HDL cholesterol but not blood pressure. European Society of Cardiology Congress; August 29, 2011. Paris.
27. Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158: 896-901.
28. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357: 2109-2122.
29. Rader DJ. Illuminating HDL - Is it still a viable therapeutic target? N Engl J Med. 2007;357:2180-2183.
30. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity. A pooled analysis of the rating atherosclerotic disease hange by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008;118(25):2515-2522.
31. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630.
32. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153-160.
33. Hu X, Dietz JD, Xia C, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. 2009;150:2211-2219.
34. Stroes ES, Kastelein JJ, Benardeau A, et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensinaldosterone system in rats. Br J Pharmacol. 2009;158:1763-1770.
35. Shinkai, H. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. Expert Opin Ther Patents. 2009;19(9): 1229-1237.
36. Gutstein DE, Krishna R, Johns D, et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther. 2012;91(1):109-122.
37. Clark RW, Ruggeri RB, Cunningham D, et al. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006;47:536-552.
38. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of cholesteryl ester transfer protein inhibition and is accompanied by an increase in circulating aldosterone levels. Br J Pharmacol. 2008;154:1465-1473.